Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLTNASDAQ:CLSDNASDAQ:ETON On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLTApplied Therapeutics$0.36-4.4%$0.41$0.30▼$10.62$51.04M23.36 million shs1.45 million shsCLSDClearside Biomedical$0.78-0.8%$0.86$0.70▼$1.65$60.61M2.11342,585 shs254,010 shsETONEton Pharmaceuticals$18.92-5.8%$15.71$3.18▼$21.48$507.40M1.22202,585 shs969,366 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLTApplied Therapeutics-4.40%-12.07%-8.18%-29.09%-91.35%CLSDClearside Biomedical-0.84%-9.89%-7.64%-9.27%-42.22%ETONEton Pharmaceuticals-5.78%-6.57%+14.74%+20.51%+411.35%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPLTApplied Therapeutics3.7772 of 5 stars3.31.00.04.71.92.50.6CLSDClearside Biomedical2.1258 of 5 stars3.55.00.00.01.80.00.0ETONEton Pharmaceuticals3.165 of 5 stars3.55.00.00.03.50.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLTApplied Therapeutics 2.50Moderate Buy$6.101,592.09% UpsideCLSDClearside Biomedical 3.00Buy$4.80515.38% UpsideETONEton Pharmaceuticals 3.00Buy$29.6756.80% UpsideCurrent Analyst Ratings BreakdownLatest ETON, CLSD, and APLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025ETONEton PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$33.00 ➝ $35.005/23/2025CLSDClearside BiomedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $5.005/16/2025CLSDClearside BiomedicalJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$5.00 ➝ $5.005/16/2025ETONEton PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $26.005/15/2025CLSDClearside BiomedicalNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$4.00 ➝ $3.005/14/2025APLTApplied TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform$1.50 ➝ $1.505/14/2025ETONEton PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$26.00 ➝ $28.004/8/2025CLSDClearside BiomedicalNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/31/2025CLSDClearside BiomedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/28/2025CLSDClearside BiomedicalChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/28/2025CLSDClearside BiomedicalNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $4.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLTApplied Therapeutics$265K192.60N/AN/A($0.20) per share-1.80CLSDClearside Biomedical$3.76M16.10N/AN/A($0.25) per share-3.12ETONEton Pharmaceuticals$48.33M10.50$0.00 per share4,502.79$0.60 per share31.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLTApplied Therapeutics-$119.76M-$0.43N/AN/AN/AN/A-260.75%-76.04%8/6/2025 (Estimated)CLSDClearside Biomedical-$32.49M-$0.41N/AN/AN/A-413.83%N/A-92.90%8/11/2025 (Estimated)ETONEton Pharmaceuticals-$940K-$0.18N/A37.84N/A-15.81%-36.29%-16.84%8/14/2025 (Estimated)Latest ETON, CLSD, and APLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025CLSDClearside Biomedical-$0.12-$0.11+$0.01-$0.11$0.20 million$2.33 million5/13/2025Q1 2025ETONEton Pharmaceuticals$0.09$0.07-$0.02-$0.06$14.33 million$17.28 million4/14/2025Q4 2024APLTApplied Therapeutics-$0.18-$0.24-$0.06$0.33$0.61 million$0.00 million3/27/2025Q4 2024CLSDClearside Biomedical-$0.13-$0.10+$0.03-$0.10$0.27 million$0.31 million3/18/2025Q4 2024ETONEton Pharmaceuticals-$0.02-$0.02N/A-$0.02$10.53 million$11.65 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLTApplied TherapeuticsN/AN/AN/AN/AN/ACLSDClearside BiomedicalN/AN/AN/AN/AN/AETONEton PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLTApplied TherapeuticsN/A1.061.06CLSDClearside BiomedicalN/A4.494.49ETONEton PharmaceuticalsN/A1.511.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLTApplied Therapeutics98.31%CLSDClearside Biomedical18.75%ETONEton Pharmaceuticals27.86%Insider OwnershipCompanyInsider OwnershipAPLTApplied Therapeutics8.60%CLSDClearside Biomedical9.20%ETONEton Pharmaceuticals16.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLTApplied Therapeutics30141.58 million106.35 millionOptionableCLSDClearside Biomedical3077.71 million68.87 millionOptionableETONEton Pharmaceuticals2026.82 million22.17 millionOptionableETON, CLSD, and APLT HeadlinesRecent News About These CompaniesEton Pharmaceuticals stock rises on FDA approval of KHINDIVIMay 29 at 7:40 PM | investing.comHydrocortisone Oral Solution Khindivi Gets FDA ApprovalMay 29 at 7:40 PM | empr.comEton Pharmaceuticals Gains on FDA Green Light for Pediatric Drug KHINDIVIMay 29 at 7:40 PM | msn.comEton Pharma wins FDA nod for oral hydrocortisone solutionMay 29 at 7:40 PM | msn.comFDA Approves Eton Pharma's Oral Drug For Adrenal Insufficiency In Pediatric Patients, Analyst Sees Boost In 2025 RevenueMay 29 at 1:20 PM | benzinga.comEton Pharmaceuticals, Inc. (ETON) Launches Game-Changer for Adrenal InsufficiencyMay 29 at 12:57 AM | insidermonkey.comEton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydrocortisone) Oral SolutionMay 28 at 5:28 PM | globenewswire.comJane Street Group LLC Has $857,000 Stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)May 26, 2025 | marketbeat.comParadigm Capital Management Inc. NY Sells 100,000 Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON)May 22, 2025 | marketbeat.comOMERS ADMINISTRATION Corp Buys New Shares in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)May 21, 2025 | marketbeat.comEton Pharmaceuticals Set To Dominate Orphan Drug NicheMay 21, 2025 | seekingalpha.comQ3 EPS Estimates for Eton Pharmaceuticals Cut by B. RileyMay 20, 2025 | marketbeat.comB. Riley Issues Pessimistic Forecast for ETON EarningsMay 20, 2025 | americanbankingnews.comCubist Systematic Strategies LLC Grows Stock Position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)May 18, 2025 | marketbeat.comParkman Healthcare Partners LLC Grows Stock Position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)May 16, 2025 | marketbeat.comEton Pharmaceuticals, Inc. (NASDAQ:ETON) Q1 2025 Earnings Call TranscriptMay 15, 2025 | msn.comMink Brook Asset Management LLC Takes $6.07 Million Position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)May 15, 2025 | marketbeat.comEton Pharmaceuticals to Participate at Upcoming Investor ConferencesMay 14, 2025 | globenewswire.comA Glimpse Into The Expert Outlook On Eton Pharmaceuticals Through 4 AnalystsMay 14, 2025 | benzinga.comQ1 2025 Eton Pharmaceuticals Inc Earnings CallMay 14, 2025 | finance.yahoo.comEton outlines path to $100M near-term revenue with ET-400 launch and Increlex growthMay 13, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeETON, CLSD, and APLT Company DescriptionsApplied Therapeutics NASDAQ:APLT$0.36 -0.02 (-4.40%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$0.37 +0.01 (+1.53%) As of 05/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.Clearside Biomedical NASDAQ:CLSD$0.78 -0.01 (-0.84%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$0.82 +0.03 (+4.49%) As of 05/29/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.Eton Pharmaceuticals NASDAQ:ETON$18.92 -1.16 (-5.78%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$19.40 +0.48 (+2.56%) As of 05/29/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
